IL96907A - Proteins produced by human lymphocytes a dna sequence coding for said proteins and their pharmaceutical and biological application - Google Patents
Proteins produced by human lymphocytes a dna sequence coding for said proteins and their pharmaceutical and biological applicationInfo
- Publication number
- IL96907A IL96907A IL9690791A IL9690791A IL96907A IL 96907 A IL96907 A IL 96907A IL 9690791 A IL9690791 A IL 9690791A IL 9690791 A IL9690791 A IL 9690791A IL 96907 A IL96907 A IL 96907A
- Authority
- IL
- Israel
- Prior art keywords
- protein
- sequence
- leu
- pro
- arg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9000126A FR2656800B1 (fr) | 1990-01-08 | 1990-01-08 | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL96907A0 IL96907A0 (en) | 1992-03-29 |
| IL96907A true IL96907A (en) | 1998-10-30 |
Family
ID=9392569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9690791A IL96907A (en) | 1990-01-08 | 1991-01-08 | Proteins produced by human lymphocytes a dna sequence coding for said proteins and their pharmaceutical and biological application |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5773578A (de) |
| EP (1) | EP0510079B1 (de) |
| JP (1) | JP2997053B2 (de) |
| AT (1) | ATE180261T1 (de) |
| DE (1) | DE69131249T2 (de) |
| DK (1) | DK0510079T3 (de) |
| ES (1) | ES2134770T3 (de) |
| FR (1) | FR2656800B1 (de) |
| GR (1) | GR3030811T3 (de) |
| IL (1) | IL96907A (de) |
| MX (1) | MX9203379A (de) |
| WO (1) | WO1991010682A1 (de) |
| ZA (1) | ZA91134B (de) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5316920A (en) * | 1992-04-17 | 1994-05-31 | Dana-Faber Cancer Institute, Inc. | Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily |
| AU755030B2 (en) * | 1994-05-06 | 2002-11-28 | Institut Gustave Roussy | LAG-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody |
| CA2189657C (fr) * | 1994-05-06 | 2002-03-12 | Florence Faure | Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype |
| US6197524B1 (en) * | 1995-07-21 | 2001-03-06 | Institute National De La Sante Et De La Recherche Medicale | Methods for detecting, identifying, isolating, and selectively labelling and targeting TH1 lymphocyte by means of the LAG-3 protein |
| PT941329E (pt) * | 1996-11-29 | 2004-11-30 | Applied Research Systems | Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3) |
| EP0900841A1 (de) * | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Spleissvarianten von LAG-3 |
| EP0893507A1 (de) | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs |
| WO2000037639A2 (en) * | 1998-12-18 | 2000-06-29 | Incyte Pharmaceuticals, Inc. | Lymphocytic membrane proteins |
| SE0103423D0 (sv) * | 2001-10-12 | 2001-10-12 | Astrazeneca Ab | Polymorphism |
| EP1575480A4 (de) * | 2002-02-22 | 2008-08-06 | Genentech Inc | Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen |
| PL1897548T5 (pl) | 2003-02-28 | 2025-03-17 | The Johns Hopkins University | Regulacja komórek T |
| KR100808925B1 (ko) | 2006-09-29 | 2008-03-03 | 고려대학교 산학협력단 | 돼지 ｌａｇ-3 융합 이뮤노글로블린 |
| EP2044949A1 (de) * | 2007-10-05 | 2009-04-08 | Immutep | Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| JP6595458B2 (ja) | 2013-09-20 | 2019-10-23 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| RU2696312C2 (ru) | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| ES2833425T3 (es) | 2014-07-16 | 2021-06-15 | Roussy Inst Gustave | Combinación de virus oncolítico con moduladores de punto de control inmunitario |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| HRP20211058T8 (hr) | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| HUE068868T2 (hu) | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| IL260021B (en) | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| US11045547B2 (en) | 2015-12-16 | 2021-06-29 | Merck Sharp & Dohme Corp. | Anti-LAG3 antibodies and antigen-binding fragments |
| WO2017156349A1 (en) | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
| EA201991673A1 (ru) | 2017-02-10 | 2020-01-17 | Регенерон Фармасьютикалз, Инк. | Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации |
| EP4286009A3 (de) | 2017-04-21 | 2024-04-03 | Sillajen, Inc. | Kombinationstherapie aus onkolytischem vacciniavirus und checkpoint-inhibitor |
| ES2965352T3 (es) | 2017-05-30 | 2024-04-12 | Bristol Myers Squibb Co | Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3) |
| CN110678200B (zh) | 2017-05-30 | 2024-05-17 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
| CN118388628A (zh) | 2019-03-29 | 2024-07-26 | 居里研究所 | 具有经修饰的生物活性的白介素-2变体 |
| EP3969040A1 (de) | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Kombination von pd-1-inhibitoren und lag-3-inhibitoren zur erhöhung der wirksamkeit bei der behandlung von krebs |
| WO2021078910A1 (en) | 2019-10-22 | 2021-04-29 | Institut Curie | Immunotherapy targeting tumor neoantigenic peptides |
| EP3824954A1 (de) | 2019-11-22 | 2021-05-26 | Centre National de la Recherche Scientifique | Vorrichtung, einrichtung und verfahren zur ministrahl-strahlentherapie |
| WO2021224186A1 (en) | 2020-05-04 | 2021-11-11 | Institut Curie | New pyridine derivatives as radiosensitizers |
| EP4153628A1 (de) | 2020-05-20 | 2023-03-29 | Institut Curie | Einzeldomänenantikörper und deren verwendung in krebstherapien |
| WO2022079270A1 (en) | 2020-10-16 | 2022-04-21 | Université D'aix-Marseille | Anti-gpc4 single domain antibodies |
| CA3196243A1 (en) | 2020-10-20 | 2022-04-28 | Angela Marinetti | Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer |
| KR20230093282A (ko) | 2020-10-23 | 2023-06-27 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 lag-3 길항제 요법 |
| US20230416196A1 (en) | 2020-11-18 | 2023-12-28 | Institut Curie | Dimer of biguanidines and their therapeutic uses |
| US20240317890A1 (en) | 2021-01-14 | 2024-09-26 | Institut Curie | Her2 single domain antibodies variants and cars thereof |
| WO2022189618A1 (en) | 2021-03-12 | 2022-09-15 | Institut Curie | Nitrogen-containing heterocycles as radiosensitizers |
| EP4337763A1 (de) | 2021-05-10 | 2024-03-20 | Institut Curie | Verfahren zur behandlung von krebs, entzündlichen erkrankungen und autoimmunerkrankungen |
| CA3227880A1 (en) | 2021-08-05 | 2023-02-09 | Marios SOTIROPOULOS | Scanning dynamic device for minibeams production |
| US20240316061A1 (en) | 2021-09-17 | 2024-09-26 | Institut Curie | Bet inhibitors for treating pab1 deficient cancer |
| WO2023089032A1 (en) | 2021-11-19 | 2023-05-25 | Institut Curie | Methods for the treatment of hrd cancer and brca-associated cancer |
| WO2023099763A1 (en) | 2021-12-03 | 2023-06-08 | Institut Curie | Sirt6 inhibitors for use in treating resistant hrd cancer |
| US20250302930A1 (en) | 2022-03-24 | 2025-10-02 | Institut Curie | Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma |
| EP4499677A1 (de) | 2022-03-31 | 2025-02-05 | Institut Curie | Modifiziertes rela-protein zur induktion der interferonexpression und manipulierte immunzellen mit verbesserter interferonexpression |
| US20250241949A1 (en) | 2022-04-07 | 2025-07-31 | Institut Curie | Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy |
| WO2023194607A1 (en) | 2022-04-07 | 2023-10-12 | Institut Curie | Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy |
| WO2024068617A1 (en) | 2022-09-26 | 2024-04-04 | Institut Curie | Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy |
| EP4680342A1 (de) | 2023-03-13 | 2026-01-21 | Regeneron Pharmaceuticals, Inc. | Kombination von pd-1-inhibitoren und lag-3-inhibitoren zur verbesserten wirksamkeit bei der behandlung von melanom |
| EP4683630A1 (de) | 2023-03-21 | 2026-01-28 | Institut Curie | Vps4b-inhibitor zur verwendung in verfahren zur behandlung von hrd-krebs |
| WO2024194673A1 (en) | 2023-03-21 | 2024-09-26 | Institut Curie | Methods for the treatment of dedifferentiated liposarcoma |
| WO2024194402A1 (en) | 2023-03-21 | 2024-09-26 | Institut Curie | Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer |
| EP4695290A1 (de) | 2023-04-13 | 2026-02-18 | Institut Curie | Verfahren zur behandlung von akuter lymphoblastischer t-zell-leukämie |
| WO2025068393A1 (en) | 2023-09-27 | 2025-04-03 | Institut Curie | Methods for the treatment of fibrotic related diseases |
| AU2024379466A1 (en) | 2023-11-15 | 2026-04-23 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer |
| EP4574165A1 (de) | 2023-12-21 | 2025-06-25 | Egle Therapeutics | Immunozytokine zur krebsbehandlung |
| WO2025133175A1 (en) | 2023-12-21 | 2025-06-26 | Egle Therapeutics | Immunocytokine for cancer treatment |
| WO2025158077A1 (en) | 2024-01-26 | 2025-07-31 | Institut Curie | Lipid degraders to trigger ferroptosis in cancer |
| WO2025202450A1 (en) | 2024-03-28 | 2025-10-02 | Institut Curie | Myeloid cells modified by cytokine chimeric receptor and uses thereof |
| EP4624494A1 (de) | 2024-03-29 | 2025-10-01 | Institut Curie | Her2-einzeldomänenantikörper und verwendungen davon |
| WO2025210252A1 (en) | 2024-04-05 | 2025-10-09 | Institut Curie | Modulators of fam118b protein for use in therapy |
| WO2026017820A1 (en) | 2024-07-18 | 2026-01-22 | Egle Therapeutics | Fusion protein for cancer treatment |
| EP4681780A1 (de) | 2024-07-18 | 2026-01-21 | Egle Therapeutics | Immunozytokine zur krebsbehandlung |
| WO2026035866A1 (en) | 2024-08-07 | 2026-02-12 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor |
| EP4707296A1 (de) | 2024-09-05 | 2026-03-11 | Egle Therapeutics | Interleukin-2-varianten mit modifizierter biologischer aktivität |
| EP4707295A1 (de) | 2024-09-05 | 2026-03-11 | Egle Therapeutics | Interleukin-2-varianten mit modifizierter biologischer aktivität |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5109123A (en) * | 1988-06-14 | 1992-04-28 | Dana Farber Cancer Institute | Alteration of ability of soluble CD4 fragments to bind HIV |
| US4994369A (en) * | 1987-12-15 | 1991-02-19 | The Board Of Trustees Of The Leland Stanford Jr. Univ. | T-cell activation related gene |
| US5001230A (en) * | 1988-02-18 | 1991-03-19 | Schering Corporation | T cell activation markers |
-
1990
- 1990-01-08 FR FR9000126A patent/FR2656800B1/fr not_active Expired - Lifetime
-
1991
- 1991-01-08 MX MX9203379A patent/MX9203379A/es unknown
- 1991-01-08 DK DK91903010T patent/DK0510079T3/da active
- 1991-01-08 JP JP3503112A patent/JP2997053B2/ja not_active Expired - Fee Related
- 1991-01-08 WO PCT/FR1991/000009 patent/WO1991010682A1/fr not_active Ceased
- 1991-01-08 ES ES91903010T patent/ES2134770T3/es not_active Expired - Lifetime
- 1991-01-08 AT AT91903010T patent/ATE180261T1/de not_active IP Right Cessation
- 1991-01-08 EP EP91903010A patent/EP0510079B1/de not_active Expired - Lifetime
- 1991-01-08 DE DE69131249T patent/DE69131249T2/de not_active Expired - Fee Related
- 1991-01-08 ZA ZA91134A patent/ZA91134B/xx unknown
- 1991-01-08 IL IL9690791A patent/IL96907A/en not_active IP Right Cessation
-
1995
- 1995-04-04 US US08/416,478 patent/US5773578A/en not_active Expired - Lifetime
- 1995-06-07 US US08/474,988 patent/US5874250A/en not_active Expired - Lifetime
-
1999
- 1999-07-20 GR GR990401899T patent/GR3030811T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US5874250A (en) | 1999-02-23 |
| ZA91134B (en) | 1992-08-26 |
| FR2656800A1 (fr) | 1991-07-12 |
| WO1991010682A1 (fr) | 1991-07-25 |
| ATE180261T1 (de) | 1999-06-15 |
| DE69131249T2 (de) | 1999-12-30 |
| IL96907A0 (en) | 1992-03-29 |
| JP2997053B2 (ja) | 2000-01-11 |
| MX9203379A (es) | 1992-09-01 |
| EP0510079B1 (de) | 1999-05-19 |
| FR2656800B1 (fr) | 1992-05-15 |
| JPH05503520A (ja) | 1993-06-10 |
| DK0510079T3 (da) | 1999-11-29 |
| DE69131249D1 (de) | 1999-06-24 |
| EP0510079A1 (de) | 1992-10-28 |
| ES2134770T3 (es) | 1999-10-16 |
| US5773578A (en) | 1998-06-30 |
| GR3030811T3 (en) | 1999-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5874250A (en) | DNA encoding for a protein containing the extracellular domain of lymphocyte activation gene 3 | |
| CA2143491C (en) | A novel peptide related to human programmed cell death and dna encoding it | |
| Jones et al. | Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1 | |
| JP3253064B2 (ja) | ウイルスの感染性を阻止するヒトライノウイルス受容体タンパク質 | |
| US5976877A (en) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses | |
| US4956281A (en) | DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 | |
| AU641134B2 (en) | A soluble molecule related to but distinct from ICAM-1 | |
| US5849699A (en) | Soluble molecule related to but distinct from ICAM-1 | |
| JP3534406B2 (ja) | 免疫グロブリンＥの高アフィニティレセプタのヒトβサブユニットの分離，特性化および用法 | |
| JP2001505407A (ja) | 腫瘍壊死因子関連リガンド | |
| NZ226475A (en) | Soluble hcd4 (t4) t-lymphocyte surface glycoprotein that binds hiv gp120 envelope protein | |
| AU642130B2 (en) | DNA sequences, recombinant DNA molecules and processes for producing PI-linked lymphocyte function associated antigen-3 | |
| AU673810B2 (en) | Secreted Mac-2-binding glycoprotein | |
| US5891434A (en) | Monoclonal antibodies to the APO-1 antigen | |
| AU662545B2 (en) | DNAs encoding proteins active in lymphocyte-mediated cytotoxicity | |
| US5683696A (en) | Cloning of duffy blood group antigen, gpD | |
| EP0702725B1 (de) | Verfahren zur herstellung rekombinanter, biologisch aktiver polypeptide | |
| US5874264A (en) | Gibbon ape leukemia virus receptor | |
| JP2005200422A (ja) | インターフェロンα／β結合タンパク質およびその製造法 | |
| US5786168A (en) | Method for recombinant production of antigen non-specific glycosylation inhibiting factor (GIF) | |
| WO1995004756A1 (en) | Complement inhibitor proteins of non-human primates | |
| AU697868C (en) | The cloning of Duffy blood group antigen | |
| JP2001523102A (ja) | アポトーシス細胞死経路の細胞内変調因子 | |
| JPH1072495A (ja) | 免疫関連因子 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |